Claris Biotherapeutics has reported visual acuity improvements with its experimental therapy CSB-001 in a proof-of-concept study involving patients with limbal stem cell deficiency (LSCD), a rare eye-surface disorder that can cause severe vision loss or blindness. Data presented at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting showed that 41.4% of treated eyes gained […]
The post Claris reports visual acuity gains with experimental LSCD treatment appeared first on Pharmafile.